SNP-ACTH Gel for Primary Membranous Nephropathy

Study Overview

A Phase 3 superiority study comparing the safety and efficacy of SNP-ACTH (1-39) Gel versus rituximab in adults with high-risk primary membranous nephropathy. The study evaluates complete remission of proteinuria at 12 months with durability confirmation at 24 months.

Inclusion Criteria

• ✓Adults aged 18 years or older
• ✓Biopsy-proven membranous nephropathy or positive anti-PLA2R antibody
• ✓High risk for progressive kidney function loss per KDIGO 2021 guidelines
• ✓eGFR ≥40 mL/min/1.73 m² by CKD-EPI formula

Exclusion Criteria

• ✗Secondary membranous nephropathy
• ✗Confirmed diagnosis of diabetes or HbA1c >6.5%
• ✗Active infection, hepatitis B/C, or tuberculosis
• ✗Non-responders to previous immunosuppressive therapies